Minerva Group Holding Valuation

Is 397 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 397 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 397's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 397's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 397?

Key metric: As 397 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 397. This is calculated by dividing 397's market cap by their current revenue.
What is 397's PS Ratio?
PS Ratio	3.5x
Sales	HK$64.82m
Market Cap	HK$225.48m

397 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 397's PS Ratio compare to its peers?

The above table shows the PS ratio for 397 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2.8x
1073 Da Yu Financial Holdings	5x	n/a	HK$234.7m
613 Planetree International Development	2.3x	n/a	HK$235.4m
2263 Fu Shek Financial Holdings	3.9x	n/a	HK$176.0m
174 Gemini Investments (Holdings)	0.1x	n/a	HK$136.6m
397 Minerva Group Holding	3.5x	n/a	HK$225.5m

Price-To-Sales vs Peers: 397 is expensive based on its Price-To-Sales Ratio (3.5x) compared to the peer average (2.8x).

Price to Sales Ratio vs Industry

How does 397's PS Ratio compare vs other companies in the HK Capital Markets Industry?

11 Companies	Price / Sales	Estimated Growth	Market Cap
3678 Holly Futures	0.9x	n/a	US$1.18b
1461 Zhongtai Futures	0.2x	n/a	US$72.11m
985 CST Group	0.3x	n/a	US$61.24m
1282 Renze Harvest International	0.4x	n/a	US$38.92m

11 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 397 is expensive based on its Price-To-Sales Ratio (3.5x) compared to the Hong Kong Capital Markets industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is 397's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

397 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3.5x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 397's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

CSC Financial

HK$197.0b

Provides investment banking services in Mainland China and internationally.

6066

HK$9.92

-2.7%

33.2%

Genertec Universal Medical Group

HK$8.8b

Offers financing and advisory services in the People’s Republic of China.

2666

HK$4.66

-3.1%

12.0%

China Renaissance Holdings

HK$4.1b

Provides investment banking and investment management services in Mainland China, Hong Kong, and the United States.

1911

HK$7.27

-26.2%